Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | TNKS | O95271 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.49 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.46 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30132372 | 0.82 | PKM (0.57) | KDM4EHPGDMAPTKMT2ASMN1; SMN2 | |
| SCHEMBL2905401 | 0.81 | PKM (0.53) | KDM4EHPGDMAPTSMN1; SMN2RXFP1 | |
| SCHEMBL3963522 | 0.78 | MAPT (0.56) | KDM4EMAPTRXFP1PKMADORA3 | |
| SCHEMBL21457878 | 0.78 | KDM4E (0.59) | KDM4EHPGDMAPTKMT2ASMN1; SMN2 | |
| SCHEMBL13151057 | 0.77 | PKM (0.56) | KDM4EMAPTRXFP1PKMMETTL3 | |
| SCHEMBL890385 | 0.77 | PKM (0.56) | KDM4EHPGDMAPTKMT2ASMN1; SMN2 | |
| SCHEMBL2901688 | 0.77 | MAPT (0.51) | KDM4EMAPTRXFP1PKMADORA3 | |
| SCHEMBL3964307 | 0.76 | PKM (0.49) | KDM4ETNKSPKMMETTL3ADORA3 | |
| SCHEMBL29143358 | 0.75 | PKM (0.54) | KDM4EHPGDMAPTKMT2ASMN1; SMN2 | |
| SCHEMBL14974510 | 0.75 | KDM4E (0.59) | KDM4EHPGDMAPTSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9505749-B2 | Quinazolinone compounds and derivatives thereof | AMGEN INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-9505749-B2 | Quinazolinone compounds and derivatives thereof | AMGEN INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-9505749-B2 | Quinazolinone compounds and derivatives thereof | AMGEN INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-20150225396-A1 | Quinazolinone Compounds and Derivatives Thereof | AMGEN INC. | 2015-08-13 | — | — | US | disclosed |
| US-20150225396-A1 | Quinazolinone Compounds and Derivatives Thereof | AMGEN INC. | 2015-08-13 | — | — | US | disclosed |
| US-20150225396-A1 | Quinazolinone Compounds and Derivatives Thereof | AMGEN INC. | 2015-08-13 | — | — | US | disclosed |
| EP-2890696-A1 | QUINAZOLINONE COMPOUNDS AND DERIVATIVES THEREOF | AMGEN, INC. (US) | 2015-07-08 | — | — | EP | disclosed |
| WO-2014036022-A1 | QUINAZOLINONE COMPOUNDS AND DERIVATIVES THEREOF | AMGEN INC. (US) | 2014-03-06 | — | — | WO | disclosed |
| WO-2014036022-A1 | QUINAZOLINONE COMPOUNDS AND DERIVATIVES THEREOF | AMGEN INC. (US) | 2014-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225396-A1 | Quinazolinone Compounds and Derivatives Thereof | TNKS, TPI1, TNKS1BP1 | KDM4E 603/4885HPGD 1369/4885MAPT 3408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.